Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

<p>Patient characteristics<a href="#t1n1" target="_blank"><sup>a</sup></a>.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	John Powderly (15026168) (author)
مؤلفون آخرون:	Martina Imbimbo (15118007) (author), Antoine Italiano (15054013) (author), Patricia Martin-Romano (22288066) (author), Meredith McKean (20432950) (author), Teresa Macarulla (15050234) (author), Eduardo Castañón Alvarez (22288069) (author), Benedito A. Carneiro (15925723) (author), Raymond Mager (17316025) (author), Vicky Barnhart (22288072) (author), Steven Eck (22288075) (author), Elina Murtomaki (19849066) (author), Arsène-Bienvenu Loembé (22288078) (author), Yun He (22288081) (author), Zachary A. Cooper (15054236) (author), Eric Tu (22288084) (author), Chunling Fan (22288087) (author), Agnes Boyer Chamard (22288090) (author), Carine Paturel (22288093) (author), Paula G. Fraenkel (22288096) (author), Antoine Hollebecque (15010338) (author)
منشور في:	2025
الموضوعات:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Combination Immunotherapy Immunotherapy Oncogenes & Tumor Suppressors PD-1 Phase I Clinical Trials
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة